{"title":"Maharat Nakhon Ratchasima医院重度子痫前期产妇体重指数与亚治疗血清镁水平的关系","authors":"Ratana Boonyongchaisawat, Siraya Kitiyodom","doi":"10.14456/TJOG.2016.25","DOIUrl":null,"url":null,"abstract":"Objectives: To evaluate association between the maternal body mass index (BMI) and subtherapeutic serum magnesium level in pregnant women with severe preeclampsia who received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Study design: Retrospective cross-sectional study. Materials and Methods: A retrospective study from October 1, 2012 to March 31, 2015 was performed to estimate the effect of maternal BMI on serum magnesium level. And 565(2.99 %) pregnant women had severe preeclampsia and eclampsia diagnosed and received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Inclusion criteria was pregnant women delivered at gestational age ≥ 24 weeks, not expectant management, received magnesium sulfate in regimen loading dose 4 grams, followed by maintenance dose 1 gram/hour intravenously, and monitored serum magnesium level. Serum magnesium level was monitored initially at 3-4 hours after loading dose, and then monitored every 4 hours during magnesium sulfate infusion. The first serum magnesium level after loading dose was used in the study. Association between maternal BMI and subtherapeutic serum magnesium level (magnesium level 1.1 gm/dL) and thrombocytopenia seem to have higher rate of therapeutic magnesium level significantly (P value < 0.05). Conclusion: Most cases of women with severe preeclampsia at Maharat Nakhon Ratchasima Hospital had subtherapeutic serum magnesium level when magnesium sulfate was administered in regimen loading dose 4 grams, followed by 1 gram per hour intravenously. Overweight and obesity were high risk factor contributing to subtherapeutic of serum magnesium level.","PeriodicalId":36742,"journal":{"name":"Thai Journal of Obstetrics and Gynaecology","volume":"24 1","pages":"145-152"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Association between Maternal Body Mass Index and Sub-therapeutic Serum Magnesium Level in Severe Preeclampsia at Maharat Nakhon Ratchasima Hospital\",\"authors\":\"Ratana Boonyongchaisawat, Siraya Kitiyodom\",\"doi\":\"10.14456/TJOG.2016.25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: To evaluate association between the maternal body mass index (BMI) and subtherapeutic serum magnesium level in pregnant women with severe preeclampsia who received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Study design: Retrospective cross-sectional study. Materials and Methods: A retrospective study from October 1, 2012 to March 31, 2015 was performed to estimate the effect of maternal BMI on serum magnesium level. And 565(2.99 %) pregnant women had severe preeclampsia and eclampsia diagnosed and received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Inclusion criteria was pregnant women delivered at gestational age ≥ 24 weeks, not expectant management, received magnesium sulfate in regimen loading dose 4 grams, followed by maintenance dose 1 gram/hour intravenously, and monitored serum magnesium level. Serum magnesium level was monitored initially at 3-4 hours after loading dose, and then monitored every 4 hours during magnesium sulfate infusion. The first serum magnesium level after loading dose was used in the study. Association between maternal BMI and subtherapeutic serum magnesium level (magnesium level 1.1 gm/dL) and thrombocytopenia seem to have higher rate of therapeutic magnesium level significantly (P value < 0.05). Conclusion: Most cases of women with severe preeclampsia at Maharat Nakhon Ratchasima Hospital had subtherapeutic serum magnesium level when magnesium sulfate was administered in regimen loading dose 4 grams, followed by 1 gram per hour intravenously. Overweight and obesity were high risk factor contributing to subtherapeutic of serum magnesium level.\",\"PeriodicalId\":36742,\"journal\":{\"name\":\"Thai Journal of Obstetrics and Gynaecology\",\"volume\":\"24 1\",\"pages\":\"145-152\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thai Journal of Obstetrics and Gynaecology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14456/TJOG.2016.25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thai Journal of Obstetrics and Gynaecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14456/TJOG.2016.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
摘要
目的:评价在Maharat Nakhon Ratchasima医院接受硫酸镁治疗的重度子痫前期孕妇的体重指数(BMI)与亚治疗期血清镁水平的关系。研究设计:回顾性横断面研究。材料与方法:回顾性研究2012年10月1日至2015年3月31日母体BMI对血清镁水平的影响。565名(2.99%)孕妇在玛哈拉特那空叻差玛医院确诊为重度子痫前期和子痫并接受硫酸镁治疗。纳入标准为:胎龄≥24周分娩的孕妇,非准用药,以方案负荷剂量4 g,维持剂量1 g /h静脉注射硫酸镁,并监测血清镁水平。在给药后3-4小时开始监测血清镁水平,在硫酸镁输注期间每4小时监测一次。研究采用负荷剂量后的第一次血清镁水平。孕妇BMI与亚治疗期血清镁水平(镁水平1.1 gm/dL)和血小板减少症的相关性明显高于治疗期血清镁水平(P值< 0.05)。结论:在以方案负荷剂量4 g硫酸镁,随后每小时静脉注射1 g硫酸镁的情况下,大多数在玛哈拉特那叻医院就诊的重度子痫前期妇女血清镁水平均达亚治疗水平。超重和肥胖是导致血清镁亚治疗的高危因素。
Association between Maternal Body Mass Index and Sub-therapeutic Serum Magnesium Level in Severe Preeclampsia at Maharat Nakhon Ratchasima Hospital
Objectives: To evaluate association between the maternal body mass index (BMI) and subtherapeutic serum magnesium level in pregnant women with severe preeclampsia who received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Study design: Retrospective cross-sectional study. Materials and Methods: A retrospective study from October 1, 2012 to March 31, 2015 was performed to estimate the effect of maternal BMI on serum magnesium level. And 565(2.99 %) pregnant women had severe preeclampsia and eclampsia diagnosed and received magnesium sulfate therapy at Maharat Nakhon Ratchasima Hospital. Inclusion criteria was pregnant women delivered at gestational age ≥ 24 weeks, not expectant management, received magnesium sulfate in regimen loading dose 4 grams, followed by maintenance dose 1 gram/hour intravenously, and monitored serum magnesium level. Serum magnesium level was monitored initially at 3-4 hours after loading dose, and then monitored every 4 hours during magnesium sulfate infusion. The first serum magnesium level after loading dose was used in the study. Association between maternal BMI and subtherapeutic serum magnesium level (magnesium level 1.1 gm/dL) and thrombocytopenia seem to have higher rate of therapeutic magnesium level significantly (P value < 0.05). Conclusion: Most cases of women with severe preeclampsia at Maharat Nakhon Ratchasima Hospital had subtherapeutic serum magnesium level when magnesium sulfate was administered in regimen loading dose 4 grams, followed by 1 gram per hour intravenously. Overweight and obesity were high risk factor contributing to subtherapeutic of serum magnesium level.